anti PD-1 CAR NK-cell therapy (Cincinnati Children's Hospital Medical Center)

N/A

Report date: 2025/03/17 09:44:09

Base Information

Drug Nameanti PD-1 CAR NK-cell therapy (Cincinnati Children's Hospital Medical Center)
Drug Alias NamePD-L1 CAR-expressing NK-92 cell therapy (Cincinnati Children's Hospital Medical Center)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProgrammed cell death protein 1 modulators
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCincinnati Children'S Hospital Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesCincinnati Children'S Hospital Medical Center
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLupus Erythematosus, Systemic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A